hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06337422 id: BE21-023 briefTitle: Bioequivalence Study of Generic Celecoxib 200 mg Capsules overallStatus: NOT_YET_RECRUITING date: 2024-09-23 date: 2024-09-27 date: 2024-10-04 date: 2024-03-29 date: 2024-04-02 name: International Bio service class: NETWORK briefSummary: To determine and compare the rate and extent of absorption of a test formulation with that of a reference innovator formulation when given as equal labeled dose in healthy subjects under fasting conditions conditions: Healthy Volunteer studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: NONE count: 40 type: ESTIMATED name: Celecoxib 200 mg capsule measure: Bioequivalence based on Cmax period measure: Bioequivalence based on AUC parameters sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06337409 id: BE24-004 briefTitle: Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2024-07-05 date: 2024-07-13 date: 2024-03-29 date: 2024-04-02 name: International Bio service class: NETWORK briefSummary: To determine and compare the rate and extent of absorption of a test formulation with that of a reference innovator formulation when given as equal labeled dose in healthy subjects under fasting conditions conditions: Healthy Volunteer studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: NONE count: 30 type: ESTIMATED name: Generic empagliflozin 25 mg film-coated tablets measure: Bioequivalence based on Cmax period measure: Bioequivalence based on AUC parameters sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06337396 id: 1001 briefTitle: Omic Approaches to Neurodevelopmental Disabilities overallStatus: COMPLETED date: 2021-05-05 date: 2023-07-28 date: 2023-12-31 date: 2024-03-29 date: 2024-03-29 name: IRCCS Eugenio Medea class: OTHER briefSummary: to bridge the gap between the molecular structure of CNV and the effect on the phenotype, considering NDDs as complex diseases, as they are a consequence of the imbalance in several dosage-sensitive genes, we might try to approach them through different --omics investigations (genomics, epigenomics, transcriptomics) according to the emerging field of network medicine. This holistic can provide valuable insight into understanding peculiar molecular mechanisms and unsuspected molecular interactions that contribute to the pathogenesis of the condition and possibly pave the way for uncovering new drug strategies that even if they do not heal the patient may improve his performance and the social interaction conditions: Neurodevelopmental Disorders studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 22 type: ACTUAL name: WGS and transcriptome analysis measure: Number of likely pathogenic structural variants measure: Number of patients for whom a genotype-phenotype correlation is found sex: ALL minimumAge: 4 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Scientific Institute IRCCS Eugenio Medea city: Bosisio Parini state: LC zip: 23842 country: Italy lat: 45.80075 lon: 9.29 hasResults: False
nctId: NCT06337383 id: 12.2021 ANGELMAN briefTitle: Study of the Prevalence of Autistic Traits in Angelman Syndrome overallStatus: RECRUITING date: 2022-03-15 date: 2024-06 date: 2024-06 date: 2024-03-29 date: 2024-04-18 name: IRCCS Eugenio Medea class: OTHER briefSummary: The goal of this observational cross-sectional study is to establish the prevalence of autism spectrum disorder in children and adolescents with Angelman syndrome. The main questions it aims to answer are:
Data from neuropsychological, speech therapy and physiotherapeutic assessments are collected during regular clinical follow-ups, regarding: cognitive development ("Bayely Scales of Infant Development-III", Cognitive Scale) and adaptive behaviour; Autism and Autism Spectrum Disorder ("Autism Diagnostic Observational Schedule-2"); parental stress and parenting styles; social-communicative skills; motor development. conditions: Angelman Syndrome studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 46 type: ESTIMATED measure: Total score of the Autism Diagnostic Observation Schedule -2 (ADOS-2), Module 1, measure: Age-equivalent score at the Cognitive Scale of the Bayley Scales of Infant Development - 3rd version (Bayley-III) measure: Total Stress score at the Parent Stress Index - 4th edition (PSI-4) questionnaire measure: Global score at the Aberrant Behaviour Checklist (ABC) measure: Total Raw score at the Social Communication Questionnaire - Current version(SCQ) sex: ALL minimumAge: 4 Years maximumAge: 14 Years stdAges: CHILD facility: I.R.C.C.S. "E.Medea" status: RECRUITING city: Conegliano state: Treviso zip: 31015 country: Italy name: Martina Baggio role: CONTACT phone: +39 340 802 1282 email: martina.baggio@lanostrafamiglia.it lat: 45.88805 lon: 12.30201 hasResults: False
nctId: NCT06337357 id: NatGerHos-Sarcopenia briefTitle: Results of Progressive Resistance Training in Older Type 2 Diabetic Patients With Sarcopenia overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-09 date: 2025-12 date: 2024-03-29 date: 2024-04-12 name: National Geriatric Hospital class: OTHER_GOV briefSummary: A randomized controlled clinical trial that will test how progressive resistance training will impact outcomes of sarcopenia in older patients with type 2 diabetes who have been diagnosed as sarcopenia. The intervention will be 12 weeks in duration with approximately 24 sessions of resistance exercises. Outcome measures will be collected at baseline, 4, 8 weeks and 12 weeks. conditions: Sarcopenia conditions: Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Progressive Resistance Training measure: Physical performance 1 - Handgrip strength measure: Physical performance 2 - Gait speed measure: Physical performance 3 - Short Physical Performance Battery (SPPB) measure: Muscle mass measure: Nutritional status measure: Health-related Quality of Life measure: Activities of Daily Living (ADLs) and Instrumental Activities of Daily Living (IADLs) sex: ALL minimumAge: 60 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Geriatric Hospital city: Hanoi zip: 100000 country: Vietnam name: Huyen TT Vu, PhD role: CONTACT phone: +84913531579 email: vuthanhhuyen11@yahoo.com lat: 21.0245 lon: 105.84117 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-01-23 uploadDate: 2024-03-22T11:34 filename: ICF_000.pdf size: 212556 hasResults: False
nctId: NCT06337344 id: HSEARS20230213007 briefTitle: Neurophysiological Effects of Mind-body Exercise in Healthy Adults overallStatus: RECRUITING date: 2024-02-01 date: 2024-04 date: 2024-04 date: 2024-03-29 date: 2024-03-29 name: The Hong Kong Polytechnic University class: OTHER briefSummary: There is some clinical evidence showing that Baduanjin (BDJ) practice, a type of mind-body based physical exercise, can improve executive function (EF). However, the neurophysiological changes associated with improved cognitive function remain elusive. Therefore, this study aims to carry out randomised controlled trial to explore how the single-session BDJ practice affect the function of prefrontal cortex(PFC) and also the EF of healthy adults, measure by fNIRS and verbal fluency test accordingly. A total of 60 healthy adults (based on power analysis 80% (β= 0.20) chance (α = 0.05, two-tailed)), aged 18 to 40 year old, without any physical, neurological, and neuropsychiatric disorder, classified as right-handed by Edinburgh Handedness Inventory, also with normal intelligence as verified by the Test of Nonverbal Intelligence will be recruited and randomly assigned to treatment(i.e. BDJ), active control(i.e, exercise), and passive control(i.e. video viewing) group. The investigator anticipate that this single-session BDJ practice will result in - (1) enhancing executive functioning , and (2) changes in functional brain activation pattern in PFC in adults. The result will give a spotlight to neurophysiological treatment effect of single-session Baduanjin on healthy adults, in developing intervention for improving executive functioning of adults. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Baduanjin name: Exercise name: Video Viewing measure: Change in cognitive function as assessed by verbal fluency task (VFT) measure: Hemodynamic changes as assessed by fNIRS sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: The Hong Kong Polytechnic University status: RECRUITING city: Hung Hom state: Kowloon country: Hong Kong name: Yvonne Han, PhD role: CONTACT phone: +852 2766 7578 lat: 22.30715 lon: 114.18532 hasResults: False
nctId: NCT06337331 id: NSH 1401 briefTitle: Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant overallStatus: NOT_YET_RECRUITING date: 2024-08-31 date: 2026-08-31 date: 2027-08-31 date: 2024-03-29 date: 2024-04-02 name: Northside Hospital, Inc. class: OTHER briefSummary: Patients eligible for a mismatch allogeneic stem cell transplant will receive Venetoclax daily for 7 days prior to transplant in addition to the following chemotherapy regimen: Decitabine daily for 5 days, Fludarabine daily for 5 days, and Busulfan daily for 2 days followed by 1 day of total body irradiation. Stem cell transplant will occur thereafter. conditions: Acute Myeloid Leukemia conditions: Myelodysplastic Syndromes studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 23 type: ESTIMATED name: Venetoclax name: Decitabine name: Fludarabine name: Busulfan name: Total Body Irradiation measure: Incidence of relapse/progression by conducting blood and bone marrow biopsy evaluations at one-year post-transplant measure: Number of patients alive at one-year post transplant measure: Number of patients alive without recurrence of disease at one-year post transplant by conducting blood and bone marrow biopsy procedures measure: Number of patients who died one year post-transplant not related to recurrence of disease measure: Number of patients who fully engrafted (blood counts fully recovered) by conducting chimerism studies at 30-, 60-, 90-, 180-, and 365-days post transplant measure: Number of patients who developed acute graft-versus-host disease by recording signs and symptoms of acute GVHD according to MAGIC standards at one-year post-transplant measure: Number of patients who developed chronic graft-versus-host disease by recording signs and symptoms of chronic GVHD according to NIH standards at one-year post-transplant measure: Number of patients who are alive at one-year post transplant who also did not develop GVHD measure: Number of patients with treatment-related adverse events to venetoclax as assessed by CTCAE v5.0 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Caitlin Guzowski city: Atlanta state: Georgia zip: 30342 country: United States lat: 33.749 lon: -84.38798 hasResults: False
nctId: NCT06337318 id: NCI-2024-02361 id: NCI-2024-02361 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: S2308 type: OTHER domain: SWOG id: S2308 type: OTHER domain: CTEP id: U10CA180888 type: NIH link: https://reporter.nih.gov/quickSearch/U10CA180888 briefTitle: Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma overallStatus: NOT_YET_RECRUITING date: 2024-08-31 date: 2032-03-31 date: 2032-03-31 date: 2024-03-29 date: 2024-04-05 name: National Cancer Institute (NCI) class: NIH briefSummary: This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden. conditions: Classic Follicular Lymphoma conditions: Follicular Lymphoma With Unusual Cytological Features studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 600 type: ESTIMATED name: Biospecimen Collection name: Computed Tomography name: Mosunetuzumab name: Positron Emission Tomography name: Rituximab name: Rituximab and Hyaluronidase Human measure: 3-year milestone progression free survival (PFS) measure: PFS measure: Overall survival measure: Overall response rate measure: Event free survival (EFS) measure: Incidence of adverse events measure: Restricted chance of longer PFS sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06337305 id: STUDY00146138 briefTitle: Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer overallStatus: COMPLETED date: 2020-08-19 date: 2022-08-19 date: 2023-08-19 date: 2024-03-29 date: 2024-03-29 name: University of Kansas Medical Center class: OTHER briefSummary: This is a prospective cross-sectional survey-based study composed of both a retrospective chart review and 3-series patient survey. This study will help elicit potential areas throughout the perioperative course of radical cystectomy to improve patient resilience and quality of life, providing opportunity for future interventional studies. conditions: Bladder Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 74 type: ACTUAL measure: Change in resiliency as measured by the Connor-Davidson Resilience Scale (CD-RISC-25). measure: Change in quality of life in patients undergoing radical cystectomy as measured by the Functional Assessment of Cancer Therapy-Bladder-Cystectomy (FACT-Bl-Cys). measure: Change in quality of life in patients undergoing radical cystectomy as measured by the PROMIS-29. measure: Identification of clinical and demographic factors in bladder cancer patients measure: Demographics sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Kansas Medical Center city: Kansas City state: Kansas zip: 66160 country: United States lat: 39.11417 lon: -94.62746 hasResults: False
nctId: NCT06337292 id: IRB00440042 briefTitle: Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures: A Multicenter Randomized Controlled Trial acronym: iVAC overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-09-30 date: 2028-12-31 date: 2024-03-29 date: 2024-03-29 name: Major Extremity Trauma Research Consortium class: OTHER briefSummary: This is a multi-center, pragmatic, parallel arm randomized controlled trial (RCT) of 352 patients with high-risk open or closed tibial plateau fracture, high-risk open or closed tibial pilon fracture, or open tibial shaft fracture with incision \>3cm. Eligible participants will be randomized to receive either incisional negative pressure wound therapy (NPWT) or a non-suction standard-of-care wound dressing for their definitive wound management. The primary outcome will be a composite outcome to evaluate clinical status 3 months after randomization. The secondary outcomes will independently assess the components of the primary outcome. conditions: Fracture of Tibia conditions: Wound Heal conditions: Infected Wound conditions: Wound Complication conditions: Wound Dehiscence studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomization into study treatment arms (incisional NPWT or non-suction standard of care) will occur in variable permuted blocks, stratified by clinical center, in a 1:1 ratio. Patients will be randomized electronically by an online Data Management System maintained by the Coordinating Center at Johns Hopkins School of Public Health. primaryPurpose: TREATMENT masking: NONE count: 352 type: ESTIMATED name: Incisional Negative Pressure Wound Therapy (NPWT) measure: Complication composite outcome sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06337279 id: FMUUH-0322 briefTitle: Systemic Oxidative Stress Score as a Predictor of Gastric Cancer Survival and Recurrence Risk overallStatus: COMPLETED date: 2022-12-10 date: 2023-08-20 date: 2024-03-20 date: 2024-03-29 date: 2024-03-29 name: Fujian Medical University class: OTHER name: Fujian Medical University Union Hospital briefSummary: The Systemic Oxidative Stress Score (SOSS) , a comprehensive score reflecting the oxidative stress conditions in the microenvironment, can independently and effectively predict tumor burden and long-term prognosis in GC patients. Nomograms based on SOSS provide a potential and promising model for risk stratification and guiding the implementation of treatment decisions. conditions: Gastric Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 3820 type: ACTUAL measure: 5-year OS measure: 5-year DFS sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Fujian Medical University Union Hospital city: Fuzhou state: Fujian zip: 350000 country: China lat: 26.06139 lon: 119.30611 hasResults: False
nctId: NCT06337266 id: 2024KY246 briefTitle: A Novel Online Calculator to Predict Long-term Survival and Recurrence Risk of Patients With Gastric Adenocarcinoma overallStatus: COMPLETED date: 2023-01-01 date: 2023-08-20 date: 2024-03-19 date: 2024-03-29 date: 2024-03-29 name: Fujian Medical University class: OTHER name: Fujian Medical University Union Hospital briefSummary: This study aimed to develop a novel Prognostic Oxidative Stress-Immune-Inflammatory Score (POSII Score) and introduce an innovative online calculator designed to predict long-term survival and assess the recurrence risk of gastric cancer (GC). conditions: Gastric Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 3622 type: ACTUAL measure: 5-year OS measure: 5-year DFS sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Fujian Medical University Union Hospital city: Fuzhou state: Fujian zip: 350000 country: China lat: 26.06139 lon: 119.30611 hasResults: False
nctId: NCT06337253 id: MOZ202401 briefTitle: Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique overallStatus: NOT_YET_RECRUITING date: 2024-03-26 date: 2024-05-26 date: 2024-11-26 date: 2024-03-29 date: 2024-03-29 name: Malaria Consortium class: OTHER briefSummary: Seasonal malaria chemoprevention (SMC) is a highly effective community-based intervention to prevent malaria infections caused by Plasmodium falciparum in areas where the burden of malaria is high and malaria transmission is seasonal. SMC is commonly seen as a success story in the Sahel region, however, there are regions in east and southern Africa where malaria transmission is seasonal, and the burden is high. However, the same decision-making frameworks that was used in the Sahel are unlikely to be applicable to east and southern Africa due to higher pre-existing resistance to the drugs used, seasonality heterogeneity, contextual difference, and unknown cost-effectiveness, amongst others. This study aims to estimate the chemoprevention efficacy, potential upscale impact, acceptability, and feasibility of SMC with sulfadoxine-pyrimenthamine + amodiaquine (SP+AQ) medicines in Niassa Province in Mozambique.
These will be the first studies analysing the chemoprevention efficacy, feasibility, acceptability, and potential scale-up impact of SMC in Niassa Province, Mozambique The outcomes of these studies aim to guide future policy changes at local, national, and international levels and potentially allow for a historically successful program to expand in a sustained and cost-effective way beyond the Sahel region. conditions: Malaria,Falciparum conditions: Chemoprevention studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The intervention in this study is the administration of one cycle of SPAQ medicines. SPAQ medicines procured by Malaria Consortium are from one of the 3 manufacturers with WHO prequalification, with whom Malaria Consortium has framework agreements: Tridem Pharma, S Kant Healthcare Ltd, or MacLeods Pharmaceuticals Ltd.
Each monthly SMC cycle consists of one dispersible tablet of SP and three daily dispersible tablets of AQ. There are two doses of SPAQ: a lower dose for children aged three to \<12 months, and a higher dose for children aged 12 to 59 months. For children aged 12 to 59 months, the dosage comprises a single dose of a full tablet of SP 500/25mg and three daily doses of a full tablet of AQ 153mg. Those aged three to \<12 months are administered half the dose given to those aged 12 to 59 months, given as full dispersible tablets. primaryPurpose: PREVENTION masking: NONE count: 1000 type: ESTIMATED name: Sulfadoxine/pyrimethamine plus amodiaquine measure: Chemoprevention failure measure: Uncomplicated malaria within 28 days sex: ALL minimumAge: 3 Months maximumAge: 59 Months stdAges: CHILD hasResults: False
nctId: NCT06337240 id: pelvic floor exercise briefTitle: Pelvic Floor Exercises Versus Pilates on Urinary Incontinance in Chronic Obstructive Pulmonary Disease overallStatus: RECRUITING date: 2024-03-29 date: 2024-07-02 date: 2024-07-02 date: 2024-03-29 date: 2024-03-29 name: Cairo University class: OTHER briefSummary: The aim of the study is To compare between the effect of both pelvic floor and Pilates exercises on urinary incontinences in COPD patients. conditions: Urinary Incontinence studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: Pelvic floor on COPD patients name: Pilates exercises on COPD patients measure: Urinary incontinence (1 Hour and 24- Hour pad test) measure: Incontinence severity index: measure: Urinary incontinence quality of life questionnaire (I-QOL) measure: Cough symptoms score measure: Cough symptoms questionnaire measure: The COPD Assessment Tool (CAT) sex: FEMALE minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Physical Therapy status: RECRUITING city: Cairo country: Egypt name: Donia El masry, doctorate role: CONTACT phone: 01005587119 email: donia.elmasry@cu.edu.eg lat: 30.06263 lon: 31.24967 hasResults: False